Clinical Trial

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open label, multi-center, Phase Ib/II study to evaluate the safety, tolerability and efficacy of SHR-4375 injection in combination with other antitumor therapies in patients with advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-09.
Status change: Not Yet Recruiting → Recruiting 2026-04-27
Trial Details
NCT Number NCT07298772
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 198 participants
Start Date 2026-01-07
Primary Completion 2027-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-01